TRAF6 promotes TGFβ-induced invasion and cell-cycle regulation via Lys63-linked polyubiquitination of Lys178 in TGFβ type i receptor

Cell Cycle

Volumn 14, Issue 4, 2015, Pages 554-565

  Sundar, Reshma ^a   Gudey, Shyam Kumar ^a   Heldin, Carl Henrik ^b   Landström, Marene ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cell cycle; Cyclin D1; EMT; Invasion; Prostate cancer; Snail1; TRAF6; Transforming growth factor

Indexed keywords

CYCLIN A1; CYCLIN B1; CYCLIN D1; GREEN FLUORESCENT PROTEIN; HEMAGGLUTININ; LYSINE; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRESENILIN 1; PROTEIN; PROTEIN P73; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TWIST1 PROTEIN; UNCLASSIFIED DRUG; VIMENTIN; PROTEIN SERINE THREONINE KINASE; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL INVASION; CELL STIMULATION; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA CONTENT; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IN VITRO STUDY; MICROARRAY ANALYSIS; POINT MUTATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UBIQUITINATION; CELL CYCLE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; MALE; METABOLISM; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR INVASION;

CELL CYCLE; CELL LINE, TUMOR; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LYSINE; MALE; MICROARRAY ANALYSIS; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; STATISTICS, NONPARAMETRIC; TNF RECEPTOR-ASSOCIATED FACTOR 6; UBIQUITINATION;

EID: 84923546045     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.990302     Document Type: Article

References (43)

1. Cook LM, Shay G, Aruajo A, Lynch CC. Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases. Cancer Metast Rev 2014; 33:511-25; PMID:24414228; http://dx.doi.org/ 10.1007/s10555-014-9494-4
2. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 2012; 13:616-30; PMID:22992590; http://dx.doi.org/10.1038/nrm3434
3. Heldin CH, Landstrom M, Moustakas A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 2009; 21:166-76; PMID:19237272; http://dx.doi.org/ 10.1016/j.ceb.2009.01.021
4. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-beta receptor. Nature 1994; 370:341-7; PMID:8047140; http://dx. doi.org/10.1038/370341a0
5. Groppe J, Hinck CS, Samavarchi-Tehrani P, Zubieta C, Schuermann JP, Taylor AB, Schwarz PM, Wrana JL, Hinck AP. Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol Cell 2008; 29:157-68; PMID:18243111; http://dx.doi. org/10.1016/j.molcel.2007.11.039
6. Massagu-e J. TGFbeta in Cancer. Cell 2008; 134:215-30; PMID:18662538; http://dx.doi.org/10.1016/j. cell.2008.07.001
7. Mu Y, Gudey SK, Landstrom M. Non-Smad signaling pathways. Cell Tissue Res 2012; 347:11-20; PMID:21701805; http://dx.doi.org/10.1007/s00441-011-1201-y
8. Souchelnytskyi S, Tamaki K, Engstrom U, Wernstedt C, ten Dijke P, Heldin CH. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J Biol Chem 1997; 272:28107-15; PMID:9346966; http:// dx.doi.org/10.1074/jbc.272.44.28107
9. Macias-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana JL. MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996; 87:1215-24; PMID:8980228; http://dx.doi.org/ 10.1016/S0092-8674(00)81817-6
10. Massagué J. TGF-beta signal transduction. 1998; 67
11. Thakur N, Sorrentino A, Heldin CH, Landstrom M. TGF-beta uses the E3-ligase TRAF6 to turn on the kinase TAK1 to kill prostate cancer cells. Fut Oncol 2009; 5:1-3; PMID:19243289; http://dx.doi.org/ 10.2217/14796694.5.1.1
12. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 2000; 19:1745-54; PMID:10775259; http://dx.doi.org/ 10.1093/emboj/19.8.1745
13. Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J Cell Sci 2005; 118:3573-84; PMID:16105881; http://dx.doi.org/10.1242/jcs.02554
14. Derynck R, Zhang YE. Smad-dependent and Smadindependent pathways in TGF-beta family signalling. Nature 2003; 425:577-84; PMID:14534577; http:// dx.doi.org/10.1038/nature02006
15. Sorrentino A, Thakur N, Grimsby S, Marcusson A, von Bulow V, Schuster N, Zhang S, Heldin CH, Landstrom M. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 2008; 10:1199-207; PMID:18758450; http://dx.doi.org/10.1038/ncb1780
16. Yamashita M, Fatyol K, Jin C, Wang X, Liu Z, Zhang YE. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell 2008; 31:918-24; PMID:18922473; http://dx.doi.org/10.1016/j. molcel.2008.09.002
17. Kirkin V, Dikic I. Ubiquitin networks in cancer. Curr Opin Genet Dev 2011; 21:21-8; PMID:21071203; http://dx.doi.org/10.1016/j.gde.2010.10.004
18. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67:425-79; PMID:9759494; http://dx.doi.org/10.1146/annurev.biochem.67.1.425
19. Bennett EJ, Harper JW. DNA damage: ubiquitin marks the spot. Nat Struct Mol Biol 2008; 15:20-2; PMID:18176551; http://dx.doi.org/10.1038/nsmb0108-20
20. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009; 458:438-44; PMID:19325623; http://dx.doi.org/10.1038/nature07960
21. Kravtsova-Ivantsiv Y, Ciechanover A. Non-canonical ubiquitin-based signals for proteasomal degradation. J Cell Sci 2012; 125:539-48; PMID:22389393; http:// dx.doi.org/10.1242/jcs.093567
22. Pickart CM, Fushman D. Polyubiquitin chains: polymeric protein signals. Curr Opin Chem Biol 2004; 8:610-6; PMID:15556404; http://dx.doi.org/10.1016/ j.cbpa.2004.09.009
23. Mu Y, Sundar R, Thakur N, Ekman M, Gudey SK, Yakymovych M, Hermansson A, Dimitriou H, Ben-goechea-Alonso MT, Ericsson J, et al. TRAF6 ubiquitinates TGFbeta type I receptor to promote its cleavage and nuclear translocation in cancer. Nat Commun 2011; 2:330; PMID:21629263; http://dx.doi.org/ 10.1038/ncomms1332
24. Gudey SK, Sundar R, Mu Y,Wallenius A, Zang G, Bergh A, Heldin CH, Landstrom M. TRAF6 stimulates the tumor-promoting effects of TGFbeta type I receptor through polyubiquitination and activation of presenilin 1. Sci Signaling 2014; 7:ra2; PMID:24399296; http://dx.doi. org/10.1126/scisignal.2004207
25. Thakur N, Gudey SK, Marcusson A, Fu JY, Bergh A, Heldin CH, Landstrom M. TGFbeta-induced invasion of prostate cancer cells is promoted by c-Jun-dependent transcriptional activation of Snail1. Cell Cycle 2014; 13; PMID:24945502; http://dx.doi.org/10.4161/ cc.29339
26. Gudey SK, Wallenius A, Landstrom M. Regulated intramembrane proteolysis of the TGFbeta type I receptor conveys oncogenic signals. Fut Oncol 2014; 10:1853-61; PMID:24597658; http://dx.doi.org/ 10.2217/fon.14.45
27. Piek E, Franzen P, Heldin CH, ten Dijke P. Characterization of a 60-kDa cell surface-associated transforming growth factor-beta binding protein that can interfere with transforming growth factor-beta receptor binding. J Cell Physiol 1997; 173:447-59; PMID:9369958; http://dx.doi.org/10.1002/(SICI)1097-4652(199712) 173:3%3c447::AID-JCP17%3e3.0.CO;2-8
28. Landstrom M. The TAK1-TRAF6 signalling pathway. Int J Biochem Cell Biol 2010; 42:585-9; PMID:20060931; http://dx.doi.org/10.1016/j. biocel.2009.12.023
29. De Boeck M, ten Dijke P. Key role for ubiquitin protein modification in TGFbeta signal transduction. Upsala J Med Sci 2012; 117:153-65; PMID:22335355; http://dx. doi.org/10.3109/03009734.2012.654858
30. Zhang L, Zhou F, Garcia de Vinuesa A, de Kruijf EM, Mesker WE, Hui L, Drabsch Y, Li Y, Bauer A, Rousseau A, et al. TRAF4 promotes TGF-beta receptor signaling and drives breast cancer metastasis. Mol Cell 2013; 51:559-72; PMID:23973329; http://dx.doi.org/ 10.1016/j.molcel.2013.07.014
31. Tessema M, Lehmann U, Kreipe H. Cell cycle and no end. Virchows Archiv: Int J Pathol 2004; 444:313-23; PMID:14968363; http://dx.doi.org/10.1007/s00428-003-0971-3
32. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004; 145:5439-47; PMID:15331580; http://dx.doi.org/10.1210/en.2004-0959
33. Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging 2012; 4:159-65; PMID:22394614
34. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/ MAPK mitogenic signaling. Genes Dev 1998; 12:3008-19; PMID:9765203; http://dx.doi.org/ 10.1101/gad.12.19.3008
35. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8:729-40; PMID:17667954; http://dx. doi.org/10.1038/nrm2233
36. Leontieva OV, Lenzo F, Demidenko ZN, Blagosklonny MV. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells. Cell Cycle 2012; 11:4642-9; PMID:23187803; http://dx.doi.org/ 10.4161/cc.22937
37. Leontieva OV, Demidenko ZN, Blagosklonny MV.MEK drives cyclin D1 hyperelevation during geroconversion. Cell Death Differ 2013; 20:1241-9; PMID:23852369; http://dx.doi.org/10.1038/cdd.2013.86
38. Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, Brown PH. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 2008; 27:366-77; PMID:17637753; http://dx.doi.org/ 10.1038/sj.onc.1210643
39. Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A, Pestell RG. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995; 270:23589-97; PMID:7559524; http://dx.doi.org/10.1074/ jbc.270.40.23589
40. Wisdom R, Johnson RS, Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J 1999; 18:188-97; PMID:9878062 [http://dx.doi.org/10.1093/emboj/18.1.188
41. Ryseck RP, Hirai SI, Yaniv M, Bravo R. Transcriptional activation of c-jun during the G0/G1 transition in mouse fibroblasts. Nature 1988; 334:535-7; PMID:3136397; http://dx.doi.org/10.1038/334535a0
42. Lamouille S, Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 2007; 178:437-51; PMID:17646396; http:// dx.doi.org/10.1083/jcb.200611146
43. Franzen P, IchijoH,Miyazono K.Different signalsmediate transforming growth factor-beta 1-induced growth inhibition and extracellular matrix production in prostatic carcinoma cells. Exp Cell Res 1993; 207:1-7; PMID:7686495; http://dx.doi.org/10.1006/excr.1993.1156